The drug is thought to restore muscle regeneration, increase muscle mass, and reduce inflammation and scar tissue accumulation in boys with DMD, a progressive muscle-wasting disease that mostly ...

Vyloy is the first CLDN18.2-targeting drug to reach the US market but has already been approved in Japan as well as in the EU and GB. Astellas refiled its marketing application in May, and the FDA ...